The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
about
Emerging approaches in Parkinson's disease - adjunctive role of safinamideParkinson's disease, antiparkinson medicines, and driving.Through scaffold modification to 3,5-diaryl-4,5-dihydroisoxazoles: new potent and selective inhibitors of monoamine oxidase B.Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.
P2860
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
@ast
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
@en
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
@nl
type
label
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
@ast
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
@en
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
@nl
prefLabel
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
@ast
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
@en
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
@nl
P2860
P1476
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
@en
P2093
Santiago Perez-Lloret
P2860
P304
P356
10.1586/14737175.2016.1150783
P577
2016-02-05T00:00:00Z